<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332024000300128</article-id>
<article-id pub-id-type="doi">10.24875/rccar.21000149</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Eventos adversos del uso de amiodarona]]></article-title>
<article-title xml:lang="en"><![CDATA[Adverse events of amiodarone use]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Solano-Caycedo]]></surname>
<given-names><![CDATA[María C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palacio-Mejía]]></surname>
<given-names><![CDATA[María I.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Zapata]]></surname>
<given-names><![CDATA[Paola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fajardo-Andrade]]></surname>
<given-names><![CDATA[Luis A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad CES Facultad de Medicina Departamento de Epidemiología]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro de Investigaciones Servicio de Epidemiología ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Clínica Cardio VID Servicio de Cardiología ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<volume>31</volume>
<numero>3</numero>
<fpage>128</fpage>
<lpage>133</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332024000300128&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332024000300128&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332024000300128&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: La amiodarona es un fármaco antiarrítmico ampliamente utilizado para la prevención y el tratamiento de arritmias supraventriculares y ventriculares. Sin embargo, se puede asociar a diversos eventos adversos. En Colombia son pocos los estudios sobre eventos adversos relacionados con este medicamento.  Objetivo: Determinar las características demográficas, clínicas y farmacológicas asociadas a eventos adversos en pacientes con uso de amiodarona en una clínica cardiovascular de la ciudad de Medellín.  Materiales y método: Estudio observacional analítico de cohorte retrospectivo, basado en la revisión de historias clínicas de pacientes tratados con amiodarona durante el periodo 2008 a 2021. Se realizó un análisis univariado, bivariado y multivariado mediante regresión logística binomial.  Resultados: Se revisaron 553 historias clínicas, de las cuales 221 cumplieron los criterios de elegibilidad. La edad promedio fue 63 años, con predominio del sexo masculino (57.5%). La mayoría presentó multimorbilidad (73.3%) y el diagnóstico más común para la prescripción de amiodarona fue la fibrilación auricular (84.4%). Se reportaron 71 (32.1%) eventos adversos relacionados con amiodarona, de los cuales los más frecuentes fueron los de origen cardiovascular (43.7%), seguidos por los tiroideos (29.6%) y por los oftalmológicos (10%). La variable que explicó la presencia evento adverso por amiodarona fue multimorbilidad (riesgo relativo &#8211;RR&#8211; ajustado 1.65; IC 95%: 1.02-2.25; p = 0.039).  Conclusiones: Los eventos adversos por amiodarona fueron frecuentes. La característica que explica el 16.8% R²N (Nagelkerke’s R2) de los eventos adversos fue multimorbilidad y la mayoría de los pacientes requirieron la suspensión del tratamiento.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Amiodarone is an antiarrhythmic drug widely used to treat and prevent supraventricular and ventricular arrhythmias. However, it can be associated with various adverse events. In Colombia there are few studies conducted on adverse events with amiodarone.  Objective: To determine the demographic, clinical and pharmacological characteristics associated with the presence of adverse events in patients with amiodarone use in a cardiovascular clinic in the city of Medellín.  Materials and method: Retrospective observational analytical cohort study, was conducted by means a review of the clinical records of patients treated with amiodarone during the period from 2008 to 2021. An univariate, bivariate and multivariate analysis was performed through binomial logistic regression.  Results: A total of 553 medical records were reviewed, of which 221 met the eligibility criteria. The mean age was 63 years and the male sex predominated (57.5%). The majority presented multimorbidity (73.3%), the most common diagnosis for the prescription of amiodarone was atrial fibrillation (84.4%). 71 (32.1%) of adverse events related to amiodarone were reported; being more frequent those of cardiovascular origin (43.7%), followed by thyroid (29.6%) and ophthalmological (10%). The variable that was associated with an adverse event due to amiodarone was multimorbidity (adjusted relative risk [RR] 1.65; IC 95%: 1.02-2.25; p = 0.039).  Conclusions: Amiodarone adverse events were common. The characteristic that explains 16.8% R²N (Nagelkerke’s R2) adverse event was multimorbidity and the majority of patients required the suspension of treatment.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Amiodarona]]></kwd>
<kwd lng="es"><![CDATA[Factores de riesgo]]></kwd>
<kwd lng="es"><![CDATA[Efectos adversos]]></kwd>
<kwd lng="es"><![CDATA[Arritmia]]></kwd>
<kwd lng="en"><![CDATA[Amiodarone]]></kwd>
<kwd lng="en"><![CDATA[Risk factors]]></kwd>
<kwd lng="en"><![CDATA[Adverse events]]></kwd>
<kwd lng="en"><![CDATA[Arrhythmia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amiodarone:historical development and pharmacologic profile]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>1983</year>
<volume>106</volume>
<numero>4 Pt 2</numero>
<issue>4 Pt 2</issue>
<page-range>788-97</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zipes]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Prystowsky]]></surname>
<given-names><![CDATA[EN]]></given-names>
</name>
<name>
<surname><![CDATA[Heger]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amiodarone:electrophysiologic actions, pharmacokinetics and clinical effects]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>1984</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1059-71</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pourbaix]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Desager]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Pacco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Harvengt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Absolute bioavailability of amiodarone in normal subjects]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>1985</year>
<volume>37</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>118-23</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Seo]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[WY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Zo]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The incidence and predictors of overall adverse effects caused by low dose amiodarone in real-world clinical practice]]></article-title>
<source><![CDATA[Korean J Intern Med]]></source>
<year>2014</year>
<volume>29</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>588-96</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenbaum]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Chiale]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Halpern]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Nau]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Przybylski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Levi]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical efficacy of amiodarone as an antiarrhythmic agent]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1976</year>
<volume>38</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>934-44</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iglesias]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Repercusiones del tratamiento con amiodarona sobre la función tiroidea y su manejo actual]]></article-title>
<source><![CDATA[Endocrinol Nutr]]></source>
<year>2007</year>
<volume>54</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>354-70</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>Food and Drug Administration</collab>
<article-title xml:lang=""><![CDATA[Information for Healthcare Professionals:Cordarone® (amiodarone HCl)]]></article-title>
<source><![CDATA[United States 2013]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)</collab>
<article-title xml:lang=""><![CDATA[Resumen de características de producto (RCP) en medicamentos]]></article-title>
<source><![CDATA[Amiodarona. Colombia]]></source>
<year>1999</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Váquez]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Olaya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacto y riesgo del tratamiento con antiarrítmicos en el control de la fibrilación auricular]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2016</year>
<volume>23</volume>
<numero>S5</numero>
<issue>S5</issue>
<page-range>118-25</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldschlager]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Naccarelli]]></surname>
<given-names><![CDATA[GV]]></given-names>
</name>
<name>
<surname><![CDATA[Olshansky]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Collard]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practice Guidelines Sub-committee, North American Society of Pacing and Electrophysiology (HRS). A practical guide for clinicians who treat patients with amiodarone:2007]]></article-title>
<source><![CDATA[Heart Rhythm]]></source>
<year>2007</year>
<volume>4</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1250-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uribe]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Arango]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Marín]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Descripción de resultados clínicos con una dosis modificada de amiodarona para la conversión de la fibrilación auricular aguda a ritmo sinusal]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2009</year>
<volume>16</volume>
<page-range>201-13</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vassallo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Trohman]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prescribing amiodarone:an evidence-based review of clinical indications]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2007</year>
<volume>298</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1312-22</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<collab>The practical guide:identification, evaluation, and treatment of overweight and obesity in adults. (2000)</collab>
<source><![CDATA[[Bethesda, Md.]. National Institutes of Health, National Heart, Lung, and Blood Institute, NHLBI Obesity Education Initiative, North American Association for the Study of Obesity]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Crilly]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Prescott]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mercer]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Defining and measuring multimorbidity:a systematic review of systematic reviews]]></article-title>
<source><![CDATA[Eur J Public Health]]></source>
<year>2019</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>182-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Medication safety in polypharmacy:technical report]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Geneva, Switzerland ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grant]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Converting an odds ratio to a range of plausible relative risks for better communication of research findings]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2014</year>
<volume>348</volume>
<page-range>f7450</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<collab>Using oral amiodarone safely</collab>
<source><![CDATA[Drug Ther Bull]]></source>
<year>2003</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>9-12</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jafari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Scheinman]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse effects of amiodarone]]></article-title>
<source><![CDATA[Pacing and Clinical Electrophysiology]]></source>
<year>1998</year>
<volume>21</volume>
<numero>I</numero>
<issue>I</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<collab>UpToDate</collab>
<source><![CDATA[Amiodarona:drug information]]></source>
<year>2021</year>
<publisher-loc><![CDATA[United States ]]></publisher-loc>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
